News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Lux Biosciences Names Dean Mitchell President and CEO
7/1/2010 6:59:27 AM
JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc. today announced the appointment of Dean Mitchell, formerly President and Chief Executive Officer of Alpharma, as President and CEO.
“Dean Mitchell brings to Lux Biosciences an outstanding track record of success in building companies and growing value at both specialty pharmaceutical companies and large global firms such as Bristol-Myers Squibb and GlaxoSmithKline,” said David Guyer, M.D., Chairman of the Lux Biosciences board of directors and Partner at SV Life Sciences. “We welcome him to the Lux Biosciences’ team and look forward to seeing the company progress under his leadership towards the U.S. and European approval and eventual commercialization of Lux’s first-in-class product for noninfectious uveitis, Luveniq™ (oral voclosporin).”
“As an oral therapy specifically developed for noninfectious uveitis, I am enthusiastic about Luveniq’s potential to help patients with this difficult-to-treat inflammatory eye disease that is an important cause of blindness,” said Mr. Mitchell. “With Lux Biosciences’ innovative portfolio of products and delivery technologies, there are multiple strategic alternatives for developing the company, and I look forward to exploring these over the coming months.”
Dean Mitchell Biography
Dean Mitchell is the former President, Chief Executive Officer and Director of Alpharma Inc., a public human and animal specialty pharmaceutical company, which was acquired by King Pharmaceuticals in December 2008. Prior to Alpharma, Mr. Mitchell was President and CEO of Guilford Pharmaceuticals, a publicly traded specialty pharmaceutical company that was acquired by MGI Pharmaceuticals in 2005. Before Guilford, Mr. Mitchell was at Bristol-Myers Squibb, where he was President, International and President, US Primary Care. Prior to BMS, Mr. Mitchell spent 14 years at GlaxoSmithKline, most recently as Senior Vice President, Clinical Development and Product Strategy. Mr. Mitchell earned his B.Sc. in Applied Biology from Coventry University in the United Kingdom and his M.B.A. from City University Business School, London, UK. He is also a non-executive Board member of ISTA Pharmaceutics, Intrexon and Talecris Biotherapeutics.
About Lux Biosciences
Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases. Lux Biosciences has exclusive worldwide rights to voclosporin for all ophthalmic indications and is cooperating with the team at Isotechnika Pharma who discovered the molecule. For more information on Lux Biosciences, please visit the company’s website at http://www.luxbio.com.
Lux Biosciences cautionary statement regarding forward-looking statements
This press release may contain forward-looking statements, including Lux Biosciences’ belief as to the medical and commercial potential of its product candidates, Lux Biosciences’ plans to pursue business and regulatory strategy, and Lux Biosciences’ expectations regarding actions and decisions solely within the control and purview of other parties. These forward-looking statements involve important known and unknown risks and uncertainties, which could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the exercise of discretion by regulatory agencies and other parties, the availability to Lux Biosciences of funds and resources to pursue research and development projects, the performance of activities and generation of scientific data by parties other than Lux Biosciences, the ability of Lux Biosciences to economically manufacture and commercialize its products once approved, acceptance by the medical community of Lux Biosciences’ products once approved and the availability of alternative therapeutic agents, approval for reimbursement by third-party payors of Lux Biosciences’ products once approved, the success and timely completion of clinical trials and other scientific studies, the ability of Lux Biosciences and its licensors to defend its and their patents from infringement by third parties, and the risk that such patents may be subsequently shown to be invalid or that the practice of such patents may infringe the patents of others. Further, Lux Biosciences disclaims any undertaking to issue further press releases or otherwise advice about changes to these beliefs, plans and expectations.